For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.
What are the rationales behind public preferences about EU risk pooling for medicines? In their article for the Journal of European Public Policy, Sharon Baute and Anniek de Ruijter found that individual preferences over the design of EU risk pooling for medicines are most strongly explained by Euroscepticism, while egalitarian ideology plays only a modest role.

In the context of the development towards a European Health Union, there are considerations for improving the access to medicines through setting up a permanent system of EU joint procurement. In their article, Baute and De Ruijter distinguish three dimensions of the policy design that are relevant within the actual debate and define the nature and intensity of EU health solidarity: scope, allocation and decision-making level. They investigate the extent to which citizens’ responsiveness to these policy dimensions of EU joint procurement of medicines is driven by Euroscepticism, egalitarianism or perceived threat. They conclude that responsiveness is loosely structured along two traditional divides: pro-EU versus anti-EU and pro-egalitarian versus antiegalitarian. Moreover, they observed that Euroscepticism is an important driving factor behind preferences about both the principle of allocation and the level of decision-making.

This article has been published in the Journal of European Public Policy

Prof. dr. mr. A. (Anniek) de Ruijter

Associate Professor of Health Law and Policy